Clinical Trials Directory

Trials / Completed

CompletedNCT06072235

Facemasks and Chronic Pain Patients With Hearing Loss

Facemasks and COVID-19 Pandemic in Chronic Pain Patients With Hearing Impairment

Status
Completed
Phase
Study type
Observational
Enrollment
500 (actual)
Sponsor
Salem Anaesthesia Pain Clinic · Academic / Other
Sex
All
Age
20 Years – 99 Years
Healthy volunteers
Accepted

Summary

Facemasks may impede communication. Impaired communication may worsen healthcare outcomes. This study explores the problem of hearing impairment in chronic pain patients, and the impact of facemasks on healthcare outcomes in chronic pain patients. Data collection includes patient's age, anxiety score, depression score, numeric pain score, and effects of facemasks on treatment outcomes. Pain is measured using numeric pain rating scale. Depression is measured using the Patient Health Questionnaire (PHQ-9) scale. Anxiety is measured using the General Anxiety Disorder (GAD-7) scale.

Detailed description

Facemasks may impede communication. Impaired communication may worsen healthcare outcomes. There is inadequate data on the prevalence of hearing impairment in chronic pain patients. There is inadequate information about the impact of facemasks on treatment outcomes in chronic pain patients with hearing impairment. This prospective study explores the problem of hearing impairment in chronic pain patients, and the impact of facemasks on healthcare outcomes in chronic pain patients. This is a prospective cohort study of adult patients undergoing pain treatment at an interventional pain clinic in Canada. Data collection includes patient's age, anxiety score, depression score, analgesic usage, numeric pain score, and effects of facemasks on pain management outcomes. Pain is measured using numeric pain rating scale of 0-10, with change of 2-points being considered significant. Depression is measured using the Patient Health Questionnaire (PHQ-9) scale of 0-27, with change of 3-points being considered significant. Anxiety is measured using the General Anxiety Disorder (GAD-7) scale of 0-21, with change of 3-points being considered significant. Data are analyzed with IBM® SPSS® Statistics 25; using Student's t-test, ANOVA, Pearson Chi-square test, and regression analysis. P-value \<0.05 is considered significant.

Conditions

Interventions

TypeNameDescription
BEHAVIORALVerbal communicationVerbal communication; by talking and listening

Timeline

Start date
2018-01-08
Primary completion
2024-12-11
Completion
2024-12-11
First posted
2023-10-10
Last updated
2025-01-27

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT06072235. Inclusion in this directory is not an endorsement.